Paris, 6th May 2026 – At the Annual Congress of the American Society of Gene & Cell Therapy (ASGCT), Vivet Therapeutics will present translational modeling data supporting the ability of its proprietary VTX-PID imlifidase formulation to enable AAV gene therapy in NAb-positive subjects :
“Modeling of VTX-PID-driven AAV3B Neutralizing Antibody Depletion Expands Treatable Populations Across Gene Therapy Platforms : From Mechanism and Clinical data to Prediction”, presented Tuesday 12th , poster 1396 at the MCEC Exhibit and Poster Hall (Halls B2-C, Exhibit Level).
Our data help de-risk and refine assumptions for any systemic gene therapy program by quantifying how realistic different scenarios are for achieving optimal positive predictive outcomes before treating patients with VTX-PID.
For any patient-centric organization, these results are highly encouraging, underscoring the potential of our translational model to optimize positive predictive outcomes, enrich for responders, and ultimately expand access to AAV gene therapy.
Vivet Therapeutics remains committed to advancing innovative therapies and supporting the gene therapy community’s progress toward greater patient access and improved clinical outcomes with VTX-PID ownership across the CMC package, including manufacturing process, non-clinical package & full clinical PK/PB model from Phase 1 dataset.
